The AGE Reader is a non-invasive monitoring device that uses ultra-violet light to excite autofluorescence in human skin tissue. The autofluorescence is from the level of Advanced Glycation End products (AGEs). The measurement of AGEs provides an immediate cardiovascular risk prediction in 12 seconds. The AGE Reader has been designed for patient friendly diagnosis and because of this allows doctors to practice personalised care and prevent disease (progression). Additionally, the method is convenient, easy to use and extensively validated.
The AGE Reader mu – connect is the answer to the need for measuring AGEs without the disadvantages of existing methods. It combines a high measurement quality standard, with an innovative design and at an attractive price level. The AGE Reader provides information that can assist physicians in diagnosing and treating patients with high cardiovascular risk. This includes patients suffering from diabetes mellitus, renal failure and also acute disorders like acute coronary syndromes and sepsis. Moreover, the device is an excellent tool for researchers in various fields.
The point-of-care measurement of AGEs offers great opportunities for multiple purposes. AGE Reader applications include:
Learn more about AGE Reader applications in:
Would you like to learn more about our products? Request any information you wish to receive here.
More information about Diagnoptics.
Information on Diagnoptics' products and Advanced Glycation Endproducts.
Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.